Imigran (Sumatriptan)

Sumatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerves, interrupting the migraine cascade.

The prescribed dose of Imigran is determined by a qualified healthcare professional based on the individual’s medical condition and response. Patients should follow the prescriber’s instructions and not exceed the recommended number of administrations per migraine episode.

Safety data for sumatriptan in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Imigran product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imigran (sumatriptan nasal spray) belongs to the triptan class, which specifically targets serotonin receptors involved in migraine. Compared with oral triptans, the nasal formulation can provide faster onset of action and is useful for patients who experience nausea or have difficulty swallowing tablets.

Imigran should be stored at room temperature, below 25 °C. Keep the spray in its original packaging, protect it from excessive moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Imigran is administered as a single spray into one nostril. The patient should tilt the head slightly forward, insert the nozzle, and depress the actuator to deliver the dose. If needed, a second dose may be taken after a minimum interval as advised by the prescriber.

The most serious risks include coronary vasospasm leading to chest pain, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Patients should seek immediate medical attention if they experience any of these symptoms.

Imigran is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, severe hepatic impairment, known hypersensitivity to sumatriptan, or those currently taking MAO inhibitors or ergot derivatives. A healthcare professional should evaluate suitability before prescribing.